Literature DB >> 20219811

Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide.

Robert Taylor1, Manish M Gandhi, Gavin Lloyd.   

Abstract

Flecainide can "organise" atrial fibrillation into atrial flutter with 1:1 conduction, leading to cardiovascular compromise. The treatment of atrial fibrillation in the emergency department is often complex and depends on several factors, including time of onset of atrial fibrillation and previously known cardiac disease. Current guidelines include flecainide as a possible treatment for chemical cardioversion and maintaining sinus rhythm in paroxysmal atrial fibrillation.1 2 An important, under-recognised complication of flecainide is the transformation of rhythm from atrial fibrillation to atrial flutter. We present four such cases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20219811     DOI: 10.1136/bmj.b4684

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  3 in total

Review 1.  Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide.

Authors:  Juan Tamargo; Jean-Yves Le Heuzey; Phillipe Mabo
Journal:  Eur J Clin Pharmacol       Date:  2015-04-15       Impact factor: 2.953

Review 2.  Revisiting an Underrecognized Strategy for Rhythm Management: Hybrid Therapy for Patients who Convert from Atrial Fibrillation to Flutter on Antiarrhythmic Drugs.

Authors:  Fady S Riad; Albert L Waldo
Journal:  J Innov Card Rhythm Manag       Date:  2019-10-15

3.  Atrial flutter with flecainide-induced 1:1 conduction at a rate <200 b.p.m. at rest: a case report.

Authors:  Sotirios Dardas; Asif Khan
Journal:  Eur Heart J Case Rep       Date:  2021-10-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.